Hoosier Cancer

Hoosier Cancer Research Network conducts innovative cancer research studies with more than 100 academic and community sites across the United States.

[Hoosier Cancer @hoosiercancer]

Congratulations to @HoosierCancer co-founder Dr. Patrick Loehrer of @IUCancerCenter, recipient of the 2026 John W. Ryan Award for Distinguished Contribution to International Programs and Studies.

Read the news from @IUGlobalHealth: https://t.co/X04zGLoxze

[Hoosier Cancer @hoosiercancer]

Congrats to @IUCancerCenter and all participating institutions for your role in the @UHhospitals-led HCRN study that led to this FDA approval. Thank you to all patients who enrolled in this trial. Advances in treatment and outcomes for patients are only possible because of you.

[IU Simon Comprehensive Cancer Center @IUCancerCenter]

A new FDA-approved bladder cancer treatment is improving outcomes for patients—with key contributions from IU researchers.

Learn how this clinical trial is helping more patients reach a cure: https://t.co/vxq9Li7IUr.

[Hoosier Cancer @hoosiercancer]

Great to connect in person with the HCRN GU Clinical Trial Working Group. Four HCRN studies were presented at the @ASCO GU Cancers Symposium, reflecting the strength of our collaborative research model.
#ASCO #GU26
Read more: https://t.co/YYps3ls9Za

[Hoosier Cancer @hoosiercancer]

CEO @BrianStemme reflects on a year of progress and collaboration at HCRN.
Read more: https://t.co/Msx5hkonqJ

[Hoosier Cancer @hoosiercancer]

Hoosier excellence, on the field and in research. 🏆
Congratulations to @IndianaFootball! At HCRN, we’re proud to collaborate with the @IUCancerCenter to advance cancer research.

[Indiana Football @IndianaFootball]

Perfection.

[Hoosier Cancer @hoosiercancer]

The #HCRN GI Working Group met at #ASCOGI to connect, share updates, and strengthen collaboration in GI cancer research.

[Hoosier Cancer @hoosiercancer]

An HCRN study (HCRN-GI23-617) will be presented as a Trials in Progress poster at the #ASCOGI 2026 Symposium in San Francisco. The study is led by Tiago Biachi de Castria, MD, PhD, of @MoffittNews.

Read more: https://t.co/RLATkfZ3cn

[Hoosier Cancer @hoosiercancer]

@JasonBrownMDPhD
@NedaHashemi8
@nabiladra
@DrRanaMcKay
@DrChrisHoimes
@DukeCancer
@UHhospitals
@IUCancerCenter
@UCSDCancer
@KimmelCancerCtr
@UNMCCC
@WashUOncology

[Hoosier Cancer @hoosiercancer]

We are proud to celebrate the work of our members who contributed to the FDA's recent approval of Keytruda or Keytruda QLEX + EV in #MIBC. HCRN GU14-188 found neoadjuvant chemo-IO demonstrated significant downstaging prior to definitive surgery. https://t.co/ZYQrBnYcgL

[Hoosier Cancer @hoosiercancer]

Our final announcement: new co-chairs for the Thoracic Clinical Trial Working Group 🌟
Welcome Regan M. Memmott, MD, PhD (Ohio State) & Ece Cali Daylan, MD, PhD (WashU), joining Nagla Abdel Karim, MD (GWU).
👉 https://t.co/n4vbVgsqiX
#HCRN #ThoracicOncology #CancerResearch

[Hoosier Cancer @hoosiercancer]

HCRN welcomes Anna Pavlick, DO, MBA (Weill Cornell), Michael C. Lowe, MD, MA (Emory Winship), and Arkadiusz Z. Dudek, MD, PhD (Mayo Clinic) as co-chairs of the Melanoma Clinical Trial Working Group.

👉 Read more:https://t.co/n4vbVgsqiX

#HCRN #Melanoma #CancerResearch

[Hoosier Cancer @hoosiercancer]

Hoosier Cancer Research Network welcomes @IbrahimSahinMD1 (U. of Michigan Rogel Cancer Center) as co-chair of the Gastrointestinal Clinical Trial Working Group, joining Patrick Boland, MD, and Sarbajit Mukherjee, MD, MS.

🔗Read more about Dr. Sahin: https://t.co/n4vbVgsqiX

[Hoosier Cancer @hoosiercancer]

HCRN welcomes Neelima Vidula, MD (@MGHCancerCenter) & @AliConlinMD, MD, MPH (Providence Cancer Institute) as co-chairs of the Breast Cancer Clinical Trial Working Group, joining @CareyAnders1, MD (@DukeCancer).
Read more: https://t.co/n4vbVgsqiX

[Misty Dawn Shields @drshieldsmd]

My mentor Dr. Nasser Hanna @hannawants2ELCN penned his memoir titled, “My Patch: A Memoir” out NOW, trending as the TOP selling book in the Oncology category on Amazon.

Incredibly grateful for such an amazing mentor to look up to, learn from, and aspire to be one day like…

@chrisdraft @TheWRP4LC @lungoncdoc @IUCancerCenter @mrgieske @jillfeldman4 @LeciaSequist @StephenVLiu @BigTenCRC @ASCO @TheShieldsLab @SclcSMASHERS

[Hoosier Cancer @hoosiercancer]

We’re excited to see HCRN CEO Brian Stemme featured today in the Indianapolis Business Journal.

He shared his insights and expertise as a respected voice in Indiana’s thriving life sciences landscape.

Read the article:https://t.co/cAxk14hsBY (subscription may be required)

[Hoosier Cancer @hoosiercancer]

We surveyed more than 130 researchers across our network, and 72% of them said IITs have been pivotal to their careers.
HCRN’s latest report explores how investigator-initiated trials are driving oncology research forward.
Read more and download the report:https://t.co/OSCvA17h0w

[Hoosier Cancer @hoosiercancer]

@fredhutch @nsayeghmd @PGrivasMDPhD @eaonc Congratulations, Dr. Grivas!

[Hoosier Cancer @hoosiercancer]

Dipenkumar Modi, MD, of @karmanoscancer recently presented an interim analysis of the HCRN-LYM22-565 study at the @EHA_Hematology 2025 Congress.

Congratulations to Dr. Modi and all co-authors and teams participating in this clinical trial!

Read more: https://t.co/RopdzoXJjH

[Hoosier Cancer @hoosiercancer]

HCRN’s new report shares insights from a survey of more than 130 researchers across our national network, revealing key trends, challenges, and the impact of IITs on cancer research.
Read more and download the report: https://t.co/OSCvA17OQ4

[Hoosier Cancer @hoosiercancer]

Congratulations, Dr. @LeXiuning and all co-authors! We are grateful to have worked with you on this key study.

[Xiuning Le MD PhD @LeXiuning]

I am extremely thankful for the entire RAMOSE trial team, co-investigators, @hoosiercancer HCRN , clinical research staff, and pts/families to complete this large multi-center randomized investigator-initiated trial (IIT) in #EGFR #lungcancer. We will report OS and other biomarker results soon. @lungoncdoc @MDAndersonNews